Company news

Thiogenesis Therapeutics Corp news in 2026

Thiogenesis Therapeutics Corp's news releases, calls and decks from 2026, newest first.

View company

Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis

October 22, 2026

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

September 21, 2026

Thiogenesis Engages Brisco Capital for Investor Relations

September 3, 2026

Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome

July 13, 2026

Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

June 17, 2026

Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million

June 3, 2026

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

June 1, 2026

Thiogenesis Announces Non-Brokered Private Placement

May 11, 2026

Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference

April 16, 2026

Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

February 2, 2026

Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026

January 23, 2026

Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

January 13, 2026

Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar

January 5, 2026

Decks in 2026